Twist Bioscience Corporation (NASDAQ:TWST) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Twist Bioscience Corporation (NASDAQ:TWST) have been assigned an average rating of “Moderate Buy” from the ten analysts that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $90.30.

Several brokerages recently issued reports on TWST. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Twist Bioscience in a research report on Wednesday, June 24th. Guggenheim raised their price target on Twist Bioscience from $60.00 to $107.00 and gave the stock a “buy” rating in a report on Monday, June 29th. Evercore lowered Twist Bioscience from an “outperform” rating to an “in-line” rating and set a $102.00 price target on the stock. in a research note on Monday, July 6th. UBS Group set a $89.00 price objective on shares of Twist Bioscience in a report on Monday, June 15th. Finally, Canaccord Genuity Group increased their price objective on shares of Twist Bioscience from $90.00 to $120.00 and gave the company a “buy” rating in a research report on Tuesday.

Twist Bioscience Trading Down 1.5%

NASDAQ:TWST opened at $91.23 on Friday. The stock has a market capitalization of $5.68 billion, a price-to-earnings ratio of -68.59 and a beta of 2.11. Twist Bioscience has a 52 week low of $23.30 and a 52 week high of $105.47. The company has a quick ratio of 2.42, a current ratio of 2.70 and a debt-to-equity ratio of 0.03. The firm has a 50 day moving average of $77.00 and a 200 day moving average of $57.76.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings results on Monday, May 4th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.22). The firm had revenue of $110.72 million during the quarter, compared to analysts’ expectations of $107.64 million. Twist Bioscience had a negative return on equity of 26.73% and a negative net margin of 19.85%.Twist Bioscience’s revenue for the quarter was up 19.3% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.66) earnings per share. As a group, sell-side analysts anticipate that Twist Bioscience will post -2.02 earnings per share for the current fiscal year.

Insider Buying and Selling at Twist Bioscience

In related news, Director Melissa A. Starovasnik sold 500 shares of the stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $61.83, for a total value of $30,915.00. Following the transaction, the director owned 25,222 shares in the company, valued at approximately $1,559,476.26. This represents a 1.94% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Dennis Cho sold 14,205 shares of the stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $89.75, for a total transaction of $1,274,898.75. Following the completion of the transaction, the insider owned 105,141 shares in the company, valued at approximately $9,436,404.75. This trade represents a 11.90% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 60,382 shares of company stock worth $4,861,215 in the last three months. 3.08% of the stock is owned by company insiders.

Institutional Trading of Twist Bioscience

Several large investors have recently made changes to their positions in the business. Western Wealth Management LLC acquired a new stake in Twist Bioscience during the 1st quarter worth about $31,000. Strs Ohio purchased a new stake in Twist Bioscience in the 1st quarter worth approximately $33,000. GAMMA Investing LLC boosted its holdings in Twist Bioscience by 24.4% during the second quarter. GAMMA Investing LLC now owns 943 shares of the company’s stock worth $97,000 after buying an additional 185 shares in the last quarter. PNC Financial Services Group Inc. grew its position in shares of Twist Bioscience by 89.7% during the 1st quarter. PNC Financial Services Group Inc. now owns 958 shares of the company’s stock valued at $46,000 after acquiring an additional 453 shares during the period. Finally, Quarry LP acquired a new stake in Twist Bioscience in the third quarter valued at approximately $28,000.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.